Press coverage about Uroplasty (NASDAQ:UPI) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Uroplasty earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 45.2943458986086 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
NASDAQ:UPI opened at $1.22 on Friday. Uroplasty has a twelve month low of $1.05 and a twelve month high of $4.05.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://weekherald.com/2018/04/20/uroplasty-upi-earns-media-impact-rating-of-0-11.html.
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.